Cnmpa Approves Agilent'S Pd-L1 Companion Diagnostic

Agilent Technologies Has Announced That The National Medical Products Administration (Nmpa, Formerly The China Food And Drug Administration) Has Approved Its Pd-L1 Ihc 22C3 Pharmdx Assay For Use In China.The Assay Is Now Approved As A Companion Diagnostic To Identify Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (Nsclc) Whose Tumors Express Pd-L1 (Tumor Proportion Score [Tps] >1%) For First-Line Treatment With Single-Agent Keytruda, An Anti-Pd-1 Therapy Manufactured By Merck & Co., Inc. Kenilworth, Nj, U.S.A.Lung Cancer Accounts For 20% Of All Cancer Deaths In China And Is The Leading Cause Of Cancer Death There1. Nmpa Approved The Assay To Identify Advanced Nsclc Patients Whose Tumors Express Pd-L1 Tumor Proportion Score (Tps) ≥ 1% For First-Line Treatment With Keytruda Monotherapy. Keytruda, As Monotherapy, Recently Received Nmpa Approval For First-Line Treatment Of Patients With Locally Advanced Or Metastatic Nsclc Whose Tumors Express Pd-L1 Tps ≥ 1% As Determined By A Validated Test.Keytruda Is A Humanized Monoclonal Antibody That Increases The Ability Of The Body'S Immune System To Help Detect And Fight Tumor Cells. Keytruda Blocks The Interaction Between Pd-1 And Its Ligands, Pd-L1, And Pd-L2, Thereby Activating T Lymphocytes, Which May Affect Both Tumor Cells And Healthy Cells. Keytruda And Other Targeted Immunotherapies Are Revolutionizing Cancer Treatment, And Their Therapeutic Value Is Being Demonstrated In Nsclc.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!